Thromboxane prostanoid receptors enhance contractions, endothelin-1, and oxidative stress in microvessels from mice with chronic kidney disease

Hypertension

Volumn 65, Issue 5, 2015, Pages 1055-1063

  Wang, Cheng ^a,c   Luo, Zaiming ^a   Kohan, Donald ^d   Wellstein, Anton ^b   Jose, Pedro A ^e   Welch, William J ^a   Wilcox, Christopher S ^a   Wang, Dan ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

cyclooxygenase; mitochondria; oxidative stress; thromboxane; vascular remodeling

Indexed keywords

8 ISOPROSTANE; 8 ISOPROSTANE F 2 ALPHA; ALBUMIN; CREATININE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ETHIDIUM; HYDROETHIDINE; MALONALDEHYDE; MESSENGER RNA; PHENYLEPHRINE; PREPROENDOTHELIN; PREPROENDOTHELIN 1; PROTEIN P22; PROTEIN P47; REACTIVE OXYGEN METABOLITE; THROMBOXANE; THROMBOXANE B2; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERIOLE; ARTERY RESISTANCE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; HEART WEIGHT; INTRACELLULAR SPACE; KIDNEY MASS; MALE; METABOLISM; MICROVASCULATURE; MITOCHONDRION; MOUSE; MYOGRAPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE CONTRACTION; TISSUE REGENERATION; URINARY EXCRETION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHRONIC KIDNEY FAILURE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY CIRCULATION; PATHOPHYSIOLOGY; VASCULARIZATION; VASOCONSTRICTION;

ANIMALS; ARTERIOLES; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; GENE EXPRESSION REGULATION; KIDNEY; MALE; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, THROMBOXANE; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC; RNA; VASCULAR REMODELING; VASOCONSTRICTION;

EID: 84937432409     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05244     Document Type: Article

References (55)

1. Santoro A, Mandreoli M. Chronic renal disease and risk of cardiovascular morbidity-mortality. Kidney Blood Press Res. 2014; 39: 142-146. doi: 10.1159/000355789
2. Landray MJ, Emberson JR, Blackwell L, Dasgupta T, Zakeri R, Morgan MD, Ferro CJ, Vickery S, Ayrton P, Nair D, Dalton RN, Lamb EJ, Baigent C, Townend JN, Wheeler DC. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis. 2010; 56: 1082-1094. doi: 10.1053/j.ajkd.2010.07.016
3. Park J, Ahmadi SF, Streja E, Molnar MZ, Flegal KM, Gillen D, Kovesdy CP, Kalantar-Zadeh K. Obesity paradox in end-stage kidney disease patients. Prog Cardiovasc Dis. 2014; 56: 415-425. doi: 10.1016/j. pcad.2013.10.005
4. Vaziri ND, Norris KC. Reasons for the lack of salutary effects of cholesterol- lowering interventions in end-stage renal disease populations. Blood Purif. 2013; 35: 31-36. doi: 10.1159/000345176
5. Cohen DL, Townsend RR. Hypertension and kidney disease: what do the data really show?. Curr Hypertens Rep. 2012; 14: 462-467. doi: 10.1007/ s11906-012-0285-4
6. Wang D, Strandgaard S, Borresen ML, Luo Z, Connors SG, Yan Q, Wilcox CS. Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2008; 51: 184-191. doi: 10.1053/j.ajkd.2007.09.020
7. Wang D, Iversen J, Wilcox CS, Strandgaard S. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003; 64: 1381-1388. doi: 10.1046/j.1523-1755.2003.00236.x.
8. Wang D, Chen Y, Chabrashvili T, Aslam S, Borrego Conde LJ, Umans JG, Wilcox CS. Role of oxidative stress in endothelial dysfunction and enhanced responses to angiotensin II of afferent arterioles from rabbits infused with angiotensin II. J Am Soc Nephrol. 2003; 14: 2783-2789
9. Wang D, Chabrashvili T, Wilcox CS. Enhanced contractility of renal afferent arterioles from angiotensin-infused rabbits: roles of oxidative stress, thromboxane prostanoid receptors, and endothelium. Circ Res. 2004; 94: 1436-1442. doi: 10.1161/01.RES.0000129578.76799.75
10. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004; 24: 354-365
11. Kawada N, Dennehy K, Solis G, Modlinger P, Hamel R, Kawada JT, Aslam S, Moriyama T, Imai E, Welch WJ, Wilcox CS. TP receptors regulate renal hemodynamics during angiotensin II slow pressor response. Am J Physiol Renal Physiol. 2004; 287: F753-F759. doi: 10.1152/ajprenal.00423.2003
12. Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci U S A. 1985; 82: 193-197
13. Lai EY, Onozato ML, Solis G, Aslam S, Welch WJ, Wilcox CS. Myogenic responses of mouse isolated perfused renal afferent arterioles: effects of salt intake and reduced renal mass. Hypertension. 2010; 55: 983-989. doi: 10.1161/HYPERTENSIONAHA.109.149120
14. Lai EY, Luo Z, Onozato ML, Rudolph EH, Solis G, Jose PA, Wellstein A, Aslam S, Quinn MT, Griendling K, Le T, Li P, Palm F, Welch WJ, Wilcox CS. Effects of the antioxidant drug tempol on renal oxygenation in mice with reduced renal mass. Am J Physiol Renal Physiol. 2012; 303: F64-F74. doi: 10.1152/ajprenal.00005.2012
15. Schnermann J, Traynor T, Pohl H, Thomas DW, Coffman TM, Briggs JP. Vasoconstrictor responses in thromboxane receptor knockout mice: tubuloglomerular feedback and ureteral obstruction. Acta Physiol Scand. 2000; 168: 201-207. doi: 10.1046/j.1365-201x.2000.00641.x.
16. Schildknecht S, Ullrich V. Peroxynitrite as regulator of vascular prostanoid synthesis. Arch Biochem Biophys. 2009; 484: 183-189. doi: 10.1016/j. abb.2008.10.023
17. Wang D, Luo Z, Wang X, Jose PA, Falck JR, Welch WJ, Aslam S, Teerlink T, Wilcox CS. Impaired endothelial function and microvascular asymmetrical dimethylarginine in angiotensin II-infused rats: effects of tempol. Hypertension. 2010; 56: 950-955. doi: 10.1161/ HYPERTENSIONAHA.110.157115
18. Chen HC, Guh JY, Shin SJ, Tsai JH, Lai YH. Reactive oxygen species enhances endothelin-1 production of diabetic rat glomeruli in vitro and in vivo. J Lab Clin Med. 2000; 135: 309-315. doi: 10.1067/mlc.2000.105616
19. Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014; 86: 896-904. doi: 10.1038/ki.2014.143
20. Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways?. A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond). 2014; 126: 111-121. doi: 10.1042/CS20120651
21. Lesault PF, Boyer L, Pelle G, Covali-Noroc A, Rideau D, Akakpo S, Teiger E, Dubois-Randé JL, Adnot S. Daily administration of the TP receptor antagonist terutroban improved endothelial function in highcardiovascular- risk patients with atherosclerosis. Br J Clin Pharmacol. 2011; 71: 844-851. doi: 10.1111/j.1365-2125.2010.03858.x.
22. Rafnsson A, Böhm F, Settergren M, Gonon A, Brismar K, Pernow J. The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. Diabetologia. 2012; 55: 600-607. doi: 10.1007/ s00125-011-2415-y.
23. Welch WJ, Peng B, Takeuchi K, Abe K, Wilcox CS. Salt loading enhances rat renal TxA2/PGH2 receptor expression and TGF response to U-46, 619. Am J Physiol. 1997; 273(6 Pt 2): F976-F983
24. Schnackenberg C, Wilcox CS. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-isoprostaglandin f2alpha. Hypertension. 1999; 33: 424-428
25. Luo Z, Chen Y, Chen S, Welch WJ, Andresen BT, Jose PA, Wilcox CS. Comparison of inhibitors of superoxide generation in vascular smooth muscle cells. Br J Pharmacol. 2009; 157: 935-943. doi: 10.1111/j.1476-5381.2009.00259.x.
26. Modlinger P, Chabrashvili T, Gill PS, Mendonca M, Harrison DG, Griendling KK, Li M, Raggio J, Wellstein A, Chen Y, Welch WJ, Wilcox CS. RNA silencing in vivo reveals role of p22phox in rat angiotensin slow pressor response. Hypertension. 2006; 47: 238-244. doi: 10.1161/01. HYP.0000200023.02195.73
27. Luo Z, Teerlink T, Griendling K, Aslam S, Welch WJ, Wilcox CS. Angiotensin II and NADPH oxidase increase ADMA in vascular smooth muscle cells. Hypertension. 2010; 56: 498-504. doi: 10.1161/ HYPERTENSIONAHA.110.152959
28. Wang D, Chabrashvili T, Borrego L, Aslam S, Umans JG. Angiotensin II infusion alters vascular function in mouse resistance vessels: roles of O and endothelium. J Vasc Res. 2006; 43: 109-119. doi: 10.1159/000089969
29. Wang D, Iversen J, Strandgaard S. Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats. J Vasc Res. 1999; 36: 502-509. doi: 25693
30. Jaffer OA, Carter AB, Sanders PN, Dibbern ME, Winters CJ, Murthy S, Ryan AJ, Rokita AG, Prasad AM, Zabner J, Kline JN, Grumbach IM, Anderson ME. Mitochondrial-Targeted antioxidant therapy decreases transforming growth factor-β-mediated collagen production in a murine asthma model. Am J Respir Cell Mol Biol. 2015; 52: 106-115. doi: 10.1165/rcmb.2013-0519OC
31. Pung YF, Rocic P, Murphy MP, Smith RA, Hafemeister J, Ohanyan V, Guarini G, Yin L, Chilian WM. Resolution of mitochondrial oxidative stress rescues coronary collateral growth in Zucker obese fatty rats. Arterioscler Thromb Vasc Biol. 2012; 32: 325-334. doi: 10.1161/ATVBAHA.111.241802
32. Folger WH, Lawson D, Wilcox CS, Mehta JL. Response of rat thoracic aortic rings to thromboxane mimetic U-46, 619: roles of endotheliumderived relaxing factor and thromboxane A2 release. J Pharmacol Exp Ther. 1991; 258: 669-675
33. Wilcox CS, Folger WH, Welch WJ. Renal vasoconstriction with U-46, 619; role of arachidonate metabolites. J Am Soc Nephrol. 1994; 5: 1120-1124
34. Valentin F, Field MC, Tippins Jr. The mechanism of oxidative stress stabilization of the thromboxane receptor in COS-7 cells. J Biol Chem. 2004; 279: 8316-8324. doi: 10.1074/jbc.M306761200
35. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916-1923. doi: 10.1172/JCI118623
36. Kisanuki YY, Emoto N, Ohuchi T, Widyantoro B, Yagi K, Nakayama K, Kedzierski RM, Hammer RE, Yanagisawa H, Williams SC, Richardson JA, Suzuki T, Yanagisawa M. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension. 2010; 56: 121-128. doi: 10.1161/HYPERTENSIONAHA.109.138701
37. Callera GE, Tostes RC, Yogi A, Montezano AC, Touyz RM. Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPHoxidase- independent mechanisms. Clin Sci (Lond). 2006; 110: 243-253. doi: 10.1042/CS20050307
38. Viel EC, Benkirane K, Javeshghani D, Touyz RM, Schiffrin EL. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 2008; 295: H281-H288. doi: 10.1152/ajpheart.00304.2008
39. Kuznetsov AV, Kehrer I, Kozlov AV, Haller M, Redl H, Hermann M, Grimm M, Troppmair J. Mitochondrial ROS production under cellular stress: comparison of different detection methods. Anal Bioanal Chem. 2011; 400: 2383-2390. doi: 10.1007/s00216-011-4764-2
40. Pearlman A, Wilcox CS, Chen Y. Reduction of oxidative stress-induced vasoconstriction by tempol is mediated by hydrogen peroxide. Hypertens. 2006; 48: e34
41. Wilcox CS. Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther. 2010; 126: 119-145. doi: 10.1016/j. pharmthera.2010.01.003
42. Araujo M, Wilcox CS. Oxidative stress in hypertension: role of the kidney. Antioxid Redox Signal. 2014; 20: 74-101. doi: 10.1089/ars.2013.5259
43. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, Mitch WE, Harrison DG. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. 2003; 111: 1201-1209. doi: 10.1172/JCI14172
44. Campese VM. A new model of neurogenic hypertension caused by renal injury: pathophysiology and therapeutic implications. Clin Exp Nephrol. 2003; 7: 167-171. doi: 10.1007/s10157-003-0238-y.
45. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol. 2003; 30: 860-866
46. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension. 1998; 32: 488-495
47. Sparks MA, Makhanova NA, Griffiths RC, Snouwaert JN, Koller BH, Coffman TM. Thromboxane receptors in smooth muscle promote hypertension, vascular remodeling, and sudden death. Hypertension. 2013; 61: 166-173. doi: 10.1161/HYPERTENSIONAHA.112.193250
48. Rizzoni D, Porteri E, Boari GE, De Ciuceis C, Sleiman I, Muiesan ML, Castellano M, Miclini M, Agabiti-Rosei E. Prognostic significance of small-Artery structure in hypertension. Circulation. 2003; 108: 2230-2235. doi: 10.1161/01.CIR.0000095031.51492.C5
49. Schiffrin EL. Vascular remodeling in hypertension: mechanisms and treatment. Hypertension. 2012; 59: 367-374. doi: 10.1161/ HYPERTENSIONAHA.111.187021
50. Oberg BP, McMenamin E, Lucas FL, McMonagle E, Morrow J, Ikizler TA, Himmelfarb J. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 2004; 65: 1009-1016. doi: 10.1111/j.1523-1755.2004.00465.x.
51. Wilcox CS, Lin L. Vasoconstrictor prostaglandins in angiotensin-dependent and renovascular hypertension. J Nephrol. 1993; 6: 124-133
52. Benndorf RA, Schwedhelm E, Gnann A, Taheri R, Kom G, Didié M, Steenpass A, Ergün S, Böger RH. Isoprostanes inhibit vascular endothelial growth factor-induced endothelial cell migration, tube formation, and cardiac vessel sprouting in vitro, as well as angiogenesis in vivo via activation of the thromboxane A(2) receptor: a potential link between oxidative stress and impaired angiogenesis. Circ Res. 2008; 103: 1037-1046. doi: 10.1161/CIRCRESAHA.108.184036
53. Benigni A, Zoja C, Corna D, Orisio S, Longaretti L, Bertani T, Remuzzi G. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int. 1993; 44: 440-444
54. De Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol. 2014; 25: 1083-1093. doi: 10.1681/ASN.2013080830
55. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011; 57: 772-779. doi: 10.1161/ HYPERTENSIONAHA.110.167486